Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1180366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Ni Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B virus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hepatitis B virus (HBV) infection causes serious liver diseases and is a healthy problem worldwide. Although vaccines are administered to infants after birth, there is no effective medicine for HBV infection. The interferon-stimulated genes (ISGs) are important factors in the host that can aid in restraining the virus, and the C19orf66 gene has a wide-antiviral spectrum.
Methods
In this study, three SNPs in the C19orf66 gene were sequenced and genotyped, and their potential function were predicted and further verified by dual-luciferase reporter assay.
Results
Although no significant difference of genotype and allele frequency was observed between HBV patients and the controls, the genotype and allele frequency showed significant difference between HBV patients with HBsAg-positive and HBV patients with HBsAg-negative or controls. Genotype AA ( P = 0.009) and AT ( P = 0.019) of rs77076061 showed higher and lower frequency in HBV patients with HBsAg-positive than in patients with HBsAg-negative, respectively. Genotype AG of rs1979262 played a risk role in HBV patients with HBsAg-positive (13.22%) than in patients with HBsAg-negative (7.53%, P = 0.036) or controls (8.48%, P = 0.033). The frequency of allele A of rs1979262 was higher in patients with HBsAg-positive (6.61%) than in patients with HBsAg-negative (3.77%, P = 0.042), while it was the opposite for the allele G. Moreover, the associations between genotypes of SNPs in the C19orf66 gene and the ALT, AST, and DBIL level were also identified. The functional assay suggested that the SNPs might influence the C19orf66 expression by changing the connection of transcriptional factors.
Conclusion
In summary, the association between genetic polymorphisms in the C19orf66 gene and HBV infection/biochemical indices of patients was firstly identified in Yunnan Province.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
- Department of Infectious Disease and Hepatic Disease, First People's Hospital of Yunnan Province, Kunming, Yunnan, China.
- Clinical Laboratory, The People's Hospital of Maguan County, Wenshan, Yunnan, China.
- School of Public Health, Nanjing Medical University, Nanjing, China.
- Kunming Medical University, Kunming, Yunnan, China.
Zitieren
APA
Liu, N., Liu, M., Yang, J., Dong, S., Yue, M., Huang, P., Xia, X., & Zhang, A. M. (2023). Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1180366
Vancouver
Liu N, Liu M, Yang J, Dong S, Yue M, Huang P, et al. Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1180366
BibTeX
@article{Liu2023,
author = {Liu, Ni and Liu, Min and Yang, Jun and Dong, Shuwei and Yue, Ming and Huang, Peng and Xia, Xueshan and Zhang, A-Mei},
title = {Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1180366}
}
EUVIMED